EP1570273B1 - Method for predicting the response to her2-directed therapy - Google Patents

Method for predicting the response to her2-directed therapy Download PDF

Info

Publication number
EP1570273B1
EP1570273B1 EP03808454.7A EP03808454A EP1570273B1 EP 1570273 B1 EP1570273 B1 EP 1570273B1 EP 03808454 A EP03808454 A EP 03808454A EP 1570273 B1 EP1570273 B1 EP 1570273B1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
expression
phosphorylation
her2
igfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03808454.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1570273A2 (en
Inventor
Sarah S. Bacus
Bradley L. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Cell Signaling Technology Inc
Original Assignee
Ventana Medical Systems Inc
Cell Signaling Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Medical Systems Inc, Cell Signaling Technology Inc filed Critical Ventana Medical Systems Inc
Publication of EP1570273A2 publication Critical patent/EP1570273A2/en
Application granted granted Critical
Publication of EP1570273B1 publication Critical patent/EP1570273B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • This invention relates to methods for predicting the response to HER2-directed therapy in an individual.
  • Cellular growth and differentiation processes involve growth factors that exert their actions through specific receptors expressed in the surfaces of responsive cells.
  • Ligands binding to surface receptors such as those that carry an intrinsic tyrosine kinase activity, trigger a cascade of events that eventually lead to cellular proliferation and differentiation ( Carpenter et al., 1979, Biochem., 48: 193-216 ; Sachs et al., 1987, Cancer Res., 47: 1981-1986 ).
  • Receptor tyrosine kinases can be classified into several groups on the basis of sequence similarity and distinct features.
  • erbB-1 also termed EGFR or HER-1
  • erbB-2 HER-2/neu
  • Coussens et al., 1985, Science, 230: 1130-1139 Bargmann et al., 1986, Cell, Vol. 45, 649-657
  • erbB-3 HER-3
  • HER erbB
  • ErbB receptors form homodimers and heterodimers that can be stimulated by various ligands leading to downstream signaling events, the extent and nature of which depend on the combination of specific dimers and ligands.
  • HER2/neu appears to be the preferred heterodimerization partner with other members of the epidermal growth factor receptor family, but ultimately the dimers formed are determined by the ligand and the erbB receptors expressed in the cell. Not only may the ligand select the dimerization partners, but it may also influence the time course of membrane translocation, activation, and internalization of the receptor.
  • NDF/Heregulin can stimulate tyrosine phosphorylation of erbB-2 through heterodimerization with either receptors erbB-3 or erbB-4 ( Peles et al., 1992, Cell 69, 205-216 , Peles et al., 1993, EMBOJ.
  • NDF/Heregulin can either elicit a growth arrest and differentiation phenotype, resulting in morphological changes, induction of lipids, and expression of intracellular adhesion molecule-1; or it can induce a mitogenic response ( Holmes et al., 1992, Science, 256:1205-1210 ; Peles et al., 1992, Cell, 69:205-216 ; Bacus et al., 1993, Cancer Res. 53:5251-5261 ).
  • Downstream signaling after ligand binding may be determined by the set of docking proteins that may bind to the activated receptors.
  • activation of erbB receptor heterodimers is coupled to and stimulates downstream MAPK-Erk1/2 and PI3K-AKT growth and survival pathways, whose deregulation in cancer has been linked to disease progression and refractoriness to therapy ( Tzahar et al., 1996, Mol. Cell. Biol. 16, 5276-5287 ; Fukazawa et al., 1996, J. Bioi. Chem. 271, 14554-14559 , Olayioye et al., 1998, Mol. Cell. Bioi. 18, 5042-5051 ; Lange et al., 1998, J. Bioi.
  • HER-3 is a major docking site for phosphoinositide-3-kinase (PI3K).
  • PI3K phosphoinositide-3-kinase
  • NDF/Heregulin stimulation causes activation of the PI3K pathway and phosphorylation of AKT ( Altiok et al., 1999, J. Bio. Chem. 274, 32274-32278 ;; Liu et al., 1999, Biochem. Biophys. Res. Comm. 261 897-903 ; Xing et al., 2000, Nature, Med. 6 189-195 ).
  • PI3K/AKT in the signaling cascade that results from HER-3 heterodimerization with overexpressed HER-2/neu receptors in breast cancer cells; activation of PBK/AKT promotes cell survival and enhanced tumor aggressiveness ( Bacus et al., 2002, Oncogene 21, 3532-3540 ).
  • AKT2 was reported to be activated and overexpressed in HER-2/neu-overexpressing breast cancers (Id.).
  • erbB-2/HER-2 is overexpressed in 20 to 30% of all breast cancers, and its overexpression is associated with poor prognosis, suggesting that it could be used as a target for anti-tumor agents (Slamon et al., 1987; Hudziak et al., 1989; Tagliabue et al., 1991).
  • chemotherapeutic agents such as cisplatin, doxoubicin, and taxol
  • HER-2/erbB-2 antibodies might enhance cytotoxicity to chemotherapeutic agents is through the modulation of the HER-2/erbB-2 protein expression (Bacus et al., 1992 & 1993; Stancovski et al., 1991; Klapper et al., 1997 & 2000), or by interfering with DNA repair (Arteaga et al., 1994 & 2001; Pietras et al., 1994).
  • one approach is to interfere with the kinase activity of the receptor by using inhibitors that block the nucleotide binding site of HER-2/neu or EGFR (Bruns et al., 2000; Christensen et al, 2001, Erlichrnan et al., 2001, Herbst et al., 2002; Hidalgo et al, 2001; Moasser et al, 2001; Fujimura et al., 2002; Normanno et al., 2002).
  • a second approach is using ansamycins to influence the stability of HER2/neu receptors (Munster et al., 2002; Basso et al, 2002).
  • Another approach is the use of antibodies directed to various erbB receptors, specifically EGFR or HER-2/neu (Alaoui-Jamali et al., 1997; Albanell et al., 2001(a); Baselga et al., 1994 & 2002; Mendelsohn, 1990).
  • Analysis of various antibodies to HER-2/neu led to the identification of the murine monoclonal, 4D5. This antibody recognizes an extracellular epitope (amino acids 529 to 627) in the cysteine-rich II domain that resides very close to the transmembrane region.
  • HERCEPTIN® is approved for treating the 25% of women whose breast cancers overexpress erbB-2 protein or demonstrate erbB-2 gene amplification ( Cobleigh et al., 1999, J. Clin. Oncol. 17, 2639-2648 ).
  • EGFR-targeted therapies are currently under clinical investigation ( Mendelsohn & Baselga, 2000, Oncogene 19, 6550-6565 ; Xia et al., 2002, Oncogene 21, 6255-6263 ).
  • Phase I studies aim to determine the maximally tolerated dose of the drug, its optimal schedule of administration and the dose-limiting toxicities.
  • cytotoxic cancer therapies have been developed based on maximum tolerated doses (MTD), treating patients without understanding the tumor profile for likely responders.
  • MTD maximum tolerated doses
  • elucidating tumor growth and survival pathways has led to the development of tumor-targeted therapies.
  • MTD maximum tolerated doses
  • More relevant may be the determination of the optimal dose and schedule that is sufficient to inhibit cellular signaling in patient samples.
  • Biological assays for signaling biomarkers are needed to establish such a protocol.
  • BED biologically effective doses
  • cytotoxic therapies where added toxicity may not be tolerable, further supporting BED-based dosing.
  • Tumor -therapy implies that populations of likely responders exists, and can be identified.
  • This invention provides methods for predicting a response of an individual to a HER2-directed therapy.
  • the invention provides methods for identifying a mammalian tumor that does respond to a HER2-directed therapy or for identifying a subject with cancer for the therapy, wherein the mammalian tumor or cancer overexpresses HER2, the method comprising the detection of a pattern of expression and/or phosphorylation of IGFR polypeptide, in combination with the detection of a pattern of expression and/or increased as decreased phosphorylation of one or more polypeptides selected from:
  • the invention provides for methods for identifying a mammalian tumour that does not respond to a HER2-directed therapy or for identifying a subject with cancer not for the therapy, wherein the tumour or cancer over-expresses HER2, the method comprising the detection of a pattern of expression and/or phosphorylation of IGFR polypeptide in combination with the detection of a pattern of expression and/or increased or decreased phosphorylation of one or more polypeptides selected from:
  • the detected pattern is normal or increased expression of IGFR polypeptide, accompanied by decreased phosphorylation of AKT polypeptide, decreased phosphorylation of S6 ribosomal polypeptide or both in the mammalian tumor as compared to a non-tumor tissue or cell sample.
  • the detected pattern is decreased expression of IGFR polypeptide, accompanied by increased phosphorylation of S6 ribosomal polypeptide in the mammalian tumor as compared to a non-tumor tissue or cell sample.
  • the detected pattern is decreased expression of IGFR polypeptide, accompanied by increased expression of NDF polypeptide in the mammalian tumor as compared to a non-tumor tissue or cell sample; where further the detected pattern can include increased phosphorylation of S6 ribosomal polypeptide.
  • the pattern that identifies a mammalian tumor as not responding is normal or increased expression of IGFR polypeptide, accompanied by increased phosphorylation of AKT polypeptide, increased phosphorylation of S6 ribosomal polypeptide, or both in the mammalian tumor as compared to a non-tumor tissue or cell sample.
  • the detected pattern is normal or increased expression of IGFR polypeptides and decreased expression of NDF polypeptide in the mammalian turnor as compared to a non-tumor tissue or cell sample.
  • the detected pattern for selecting a subject for treatment with a molecule targeting HER2 is normal or increased expression of IGFR polypeptide, accompanied by decreased phosphorylation of AKT polypeptide, decreased phosphorylation of S6 ribosomal polypeptide or both in the mammalian tumor as compared to a non-tumor tissue or cell sample.
  • the detected pattern is decreased expression of IGFR polypeptide, accompanied by increased phosphorylation of S6 ribosomal polypeptide in the mammalian tumor as compared to a non-tumor tissue or cell sample.
  • the detected pattern is decreased expression of IGFR polypeptide, accompanied by increased expression of NDF polypeptide in the mammalian tumor as compared to a non-tumor tissue or cell sample; where further the detected pattern can include increased phosphorylation of S6 ribosomal polypeptide.
  • the detected pattern for selecting a subject not to receive treatment with a molecule targeting HER2 is normal or increased expression of IGFR polypeptide, accompanied by increased phosphorylation of AKT polypeptide, increased phosphorylation of S6 ribosomal polypeptide, or both in the mammalian tumor as compared to a non-tumor tissue or cell sample.
  • the detected pattern is normal or increased expression of IGFR polypeptide and decreased expression of NDF in the mammalian tumor as compared to a non-tumor tissue or cell sample.
  • the detection of phosphorylation of AKT polypeptide, phosphorylation of S6 ribosomal polypeptide, or both can determined subsequent to contacting the sample obtained from the mammalian tumor with a HER2-directed therapy.
  • the HER2-directed therapy can be or comprise rhuMAb HER2 (HERCEPTIN®).
  • the sample can be contacted with at least one chemotherapeutic agent.
  • the detected pattern of expression, phosphorylation, or both, of one or a plurality of polypeptides (a) through (c) can be determined using a biodetection reagent.
  • the biodetection reagent can be an antibody or a nucleic acid probe.
  • the detected pattern of phosphorylated AKT polypeptide can be determined using an antibody specific for an epitope comprising a phosphorylated serine residue at position 473, and/or the detected pattern of phosphorylated S6 ribosomal polypeptide can be determined using an antibody specific for an epitope comprising a phosphorylated serine residue at position 235.
  • the sample obtained from the mammalian tumor can be a paraffin-embedded biopsy sample.
  • the mammalian tumor can be identified as overexpressing HER2 using an antibody that binds HER2 polypeptide.
  • This invention provides methods for predicting response in cancer subjects to cancer therapy, including human cancer patients.
  • this invention provides predictive biomarkers to identify the cancer patients for whom the administering a therapeutic agent will be most effective, including a therapeutic agent for treating breast cancer.
  • this invention provides predictive biomarkers for assessing the efficacy of therapeutic agents targeted to Her2/neu, including such agents such as rhuMAb HER2 (HERCEPTIN®).
  • neoadjuvant (or primary) chemotherapy consists of administering drugs as an initial treatment in certain cancer patients.
  • One advantage of such an approach is that, for primary tumors of more than 3 cm, it permits the later or concomitant use of conservative surgical procedures (as opposed to, e.g., radical mastectomy in breast cancer patients) for the majority of patients, due to the tumor shrinking effect of the chemotherapy.
  • Another advantage is that for many cancers, a partial and/or complete response is achieved in about two-thirds of all patients.
  • the present invention provides methods for developing more informed and effective regimes of therapy that can be administered to cancer patients with an increased likelihood of an effective outcome (i.e., reduction or elimination of the tumor).
  • a cancer diagnosis both an initial diagnosis of disease and subsequent monitoring of the disease course (before, during, or after treatment) is conventionally confirmed through histological examination of cell or tissue samples removed from a patient.
  • Clinical pathologists need to be able to accurately determine whether such samples are benign or malignant and to classify the aggressiveness of tumor samples deemed to be malignant, because these determinations often form the basis for selecting a suitable course of patient treatment.
  • the pathologist needs to be able to detect the extent to which a cancer has grown or gone into remission, particularly as a result of or consequent to treatment, most particularly treatment with chemotherapeutic or biological agents.
  • Histological examination traditionally entails tissue-staining procedures that permit morphological features of a sample to be readily observed under a light microscope.
  • a pathologist after examining the stained sample, typically makes a qualitative determination of whether the tumor sample is malignant. It is difficult, however, to ascertain a tumor's aggressiveness merely through histological examination of the sample, because a tumor's aggressiveness is often a result of the biochemistry of the cells within the tumor, such as protein expression or suppression and protein phosphorylation, which may or may not be reflected by the morphology of the sample. Therefore, it is important to be able to assess the biochemistry of the cells within a tumor sample. Further, it is desirable to be able to observe and quantitate both gene expression and protein phosphorylation of tumor-related genes or proteins, or more specifically cellular components of tumor-related signaling pathways.
  • Cancer therapy can be based on molecular profiling oftumors rather than simply their histology or site of the disease. Elucidating the biological effects of targeted therapies in tumor tissue and correlating these effects with clinical response helps identify the predominant growth and survival pathways operative in tumors, thereby establishing a pattern of likely responders and conversely providing a rational for designing strategies to overcome resistance.
  • Successful diagnostic targeting of a growth factor receptor must determine if tumor growth or survival is being driven by the targeted receptor or receptor family, by other receptors not targeted by the therapy, and whether downstream signaling suggests that another oncogenic pathway is involved.
  • HERCEPTIN® For subjects considered for treatment with rhuMAb HER2 (HERCEPTIN®), it is necessary to consider additional biomarkers beyond the presence of the target HER-2/neu, at least because the status of the EGFR and erbB ligands NDF and TGF- ⁇ affect rhuMAb HER2 (HERCEPTIN®) therapy response in breast cancer patients. Therefore, considering HER2/neu expression alone does not necessarily predict overall erbB oncogenic activity or potential response to erbB inhibitors. In addition, previous studies have shown that not all tumor cells respond to inhibition of ErbB receptors, despite exhibiting aberrant EGFR and/or HER2/neu expression.
  • Examples include the MKN7 and BT474 erbB receptor-overexpressing carcinoma cell lines: BT474 cells respond to rhuMAb HER2 (HERCEPTIN®) but MKN7 cells do not ( Motoyama, et al., Cancer Research, 62, 3151-3158 (2002 )).
  • the proliferation block induced as a consequence of decreased EGFR or HER2 receptor activity such as by the activity of an erbB-inhibitor, may be overcome by the presence ofEGF-related ligands such as EGF or NDF/Heregulin (Id). This phenomenon can be attenuated using a bispecific ErbB-1/ErbB-2 inhibitor, thus supporting increased antitumor efficacy through simultaneous inhibition of multiple ErbB receptors.
  • NDF/Heregulin or TGF- ⁇ expression produces an autocrine loop of HER-2/EGFR heterodimerization.
  • Downregulation of HER-2/neu expression is an important way of inhibiting signals generated by these heterodimers. Downregulation can be accomplished by treatment with rhuMAb HER2 (HERCEPTIN®), which produces receptor endocytosis.
  • HERCEPTIN® HERCEPTIN®
  • high levels of phosphorylated ERK (or pAKT) can be a negative predictor for positive treatment outcome, when observed in conjunction with the expression of EGFR and the presence of NDF, suggesting the existence of other pathways that might promote proliferation of the tumor cellular growth.
  • High pERK is also associated with resistance to rhuMAb HER2 (HERCEPTIN®) through downregulation of p27; this may implicate other signals (such as estrogen receptor's cross activation of the MAPK and AKT pathways) that may contribute to high pERK and thus contribute to proliferation of the tumor cells growth.
  • phosphorylated AKT has been shown to be an important part of the response to rhuMAb HER2 (HERCEPTIN®), as high pAKT-positive patients had poor response to rhuMAb HER2 (HERCEPTIN®).
  • High-phosphorylated AKT has been shown to be associated with high expression of insulin like growth factor receptors (IGFR-1) as well as PDGFR and results in resistance to rhuMAb HER2 (HERCEPTIN®).
  • IGFR-1 insulin like growth factor receptors
  • PDGFR insulin like growth factor receptor
  • HERCEPTIN® results in resistance to rhuMAb HER2
  • data from clinical trials have shown that using a dual inhibitor (i.e., specific for HER-1/neu and HER-2/neu) has clinical efficacy in patients when treatment induced downregulation of pERK and pAKT, but not.in patients in which pERK and pAKT levels didn't diminish after treatment.
  • ErbB-targeted mAbs In addition to ErbB-targeted mAbs, a number of different ErbB-1/ErbB-2-bispecific inhibitors, also referred to as dual EGFR/erbB-2 kinase inhibitors, have been described recently, such as GW572016 and PKI166, that are currently in clinical trials ( Motoyama et al., 2002, Cancer Research 62: 3151-3158 ). Therefore, response to rhuMAb HER2 (HERCEPTIN®) is affected by the expression of multiple erbB receptors and their ligands in tumors.
  • HERCEPTIN® HERCEPTIN®
  • HER-2/neu overexpression alone is not the only predictor of response to molecules such as rhuMAb HER2 (HERCEPTIN®).
  • HER-2/neu is an orphan, ligandless receptor in need of its partners EGFR (HER-1) and HER-3 in order to exert its activity.
  • HER-1 and HER-3 heterodimerization with HER-2 is enhanced by the presence of EGF or NDF ( Tzahar et al., 1996, EMBO J 15: 254-64 , Graus-Porta, 1997, EMBO J., 16 1647-55 ), and thus HER-2 activity is dependant on HER-1 or HER-3.
  • Other receptors may also transactivate the erbB receptors.
  • the IGFR receptor may mediate patient response to breast cancer therapies targeting HER2/neu.
  • High IGFR expression combined with high S6 ribosomal protein phosphorylation correlates with poor patient response regardless of erb-B expression, indicating that IGFR acts directly to activate signaling downstream of erb-B receptors rather than through transactivation of erb-B receptors.
  • Cell line studies also have suggested a role for IGFR in patient response.
  • rhuMAb HER2 (HERCEPTIN®) resistance has been suggested to occur though activation of IGFR ( Lu et al., 2001, J National Cancer Institute 93: 1852 ).
  • eo-targeting IGFR as well as HER2/neu has been shown to produce synergistic inhibition of growth in breast cancer cells ( Camirand et al., 2002, Med Sci Monit. 8: (12): BR521-6 ). Therefore, analysis of IGFR expression and downstream signaling can be critical for an accurate assessment of potential rhuMAb HER2 (HERCEPTIN®) response in breast cancer patients.
  • AKT and MAP kinase pathway activation are known to play a role in response to DNA-damaging agents ( Clark et al., 2002, Mol. Cancer Ther. 1: 707- 17 ; Bacus et al., 2001, Oncogene 20: 147-155 ).
  • Consideration of downstream signalling in patients undergoing a combination of therapies provides additional predictive information not obtained solely from analysis of receptor or ligand expression levels.
  • HERCEPTIN® rhuMAb HER2
  • HERCEPTIN® rhuMAb HER2
  • the identified biomarkers are useful, among other things, for designing diagnostics for breast cancer patients undergoing the common rhuMAb HER2 (HERCEPTIN®) combination therapies.
  • pAK.T has been associated with high levels of Cyclin E and low levels of the cyclin inhibitor p27.
  • HER2-targeted therapies Before administration of HER2-targeted therapies, a panel of diagnostics of each tumor is used according to the methods of this invention to find the best candidate for each therapy.
  • treatment by a HER2-targeted therapy such as rhuMAb HER2 (HERCEPTIN®)
  • a HER2-targeted therapy such as rhuMAb HER2 (HERCEPTIN®)
  • a HER2-targeted therapy such as rhuMAb HER2 (HERCEPTIN®)
  • IGFR Insulin-like Growth Factor Receptors
  • Use of the methods of this invention permits a clinician to choose a more effective combination of targeted therapies for cancer patients.
  • the HER2-directed therapies of the present invention can include, for example, rhuMAb HER2, otherwise known as rhuMAb HER2 (HERCEPTIN®).
  • the samples obtained from the mammalian tumor can be contacted with at least one chemotherapeutic agent, for example cisplaint, doxorubicin, or taxol.
  • Automated (computer-aided) image analysis systems can augment visual examination of tumor samples.
  • the cell or tissue sample is exposed to detectably-labeled reagents specific for a particular biological marker, and the magnified image of the cell is then processed by a computer that receives the image from a charge-coupled device (CCD) or camera such as a television camera.
  • CCD charge-coupled device
  • Such a system can be used, for example, to detect and measure expression and activation levels of EGFR, HER2, HER3, pERK, NDF, TGF- ⁇ , IGFR, pS6, and pAKT in a sample, or any additional diagnostic biomarkers.
  • the methods of the invention provide more accurate cancer diagnosis and better characterization of gene expression in histologically identified cancer cells, most particularly with regard to expression of tumor marker genes or genes known to be expressed in particular cancer types and subtypes (e.g., having different degrees of malignancy). This information permits a more informed and effective regimen of therapy to be administered, because drugs with clinical efficacy for certain tumor types or subtypes can be administered to patients whose cells are so identified.
  • Another drawback of conventional anticancer therapies is that the efficacy of specific chemotherapeutic agents in treating a particular cancer in an individual human patient is unpredictable.
  • the art is unable to determine, prior to starting therapy, whether one or more selected agents would be active as anti-tumor agents or to render an accurate prognosis of course of treatment in an individual patient. This is especially important because a particular clinical cancer may present the clinician with a choice of treatment regimens, without any current way of assessing which regimen will be most efficacious for a particular individual.
  • It is an advantage of the methods of this invention that they are able to better assess the expected efficacy of a proposed therapeutic agent (or combination of agents) in an individual patient.
  • the claimed methods are advantageous for the additional reasons that they are both time- and cost-effective in assessing the efficacy of chemotherapeutic regimens and are minimally traumatic to cancer patients.
  • Methods of this invention can be used to identify a mammalian tumor that responds to HER-2 directed therapies. Further, methods of this invention can be used to select a subject with cancer for treatment with a molecule targeting HER. Moreover, methods of this invention can be used to identify a mammalian tumor that does not respond to HER-2 directed therapies. Further, methods of this invention can be used to select a subject with cancer to not receive treatment with a molecule targeting HER2.
  • Patterns of expression and phosphorylation of polypeptides are detected and quantified using methods of the present invention. More particularly, patterns of expression and phosphorylation of polypeptides that are cellular components of a turner-related signaling pathway are detected and quantified using methods of the present invention.
  • the patterns of expression and phosphorylation of polypeptides can be detected using biodetection reagents specific for the polypeptides.
  • the biodetection reagents can be antibodies.
  • the biodetection reagents can be nucleic acid probes.
  • a nucleic acid probe is defined to be a collection of one or more nucleic acid fragments whose hybridization to a sample can be detected.
  • the probe may be unlabeled or labeled so that its binding to the target or sample can be detected.
  • the probe is produced from a source of nucleic acids from one or more particular (preselected) portions of the genome, e.g., one or more clones, an isolated whole chromosome or chromosome fragment, or a collection of polymerase chain reaction (PCR) amplification products.
  • the nucleic acid probe may also be isolated nucleic acids immobilized on a solid surface (e.g., nitrocellulose, glass, quartz, fused silica slides), as in an array.
  • the probe may be a member of an array of nucleic acids as described, for instance, in WO 96/17958 .
  • nucleic acid refers to a deoxyribonucleotide or ribonucleotide in either single- or double-stranded form.
  • the term encompasses nucleic acids, i.e., oligonucleotides, containing known analogues of natural nucleotides that have similar or improved binding properties, for the purposes desired, as the reference nucleic acid.
  • the term also includes nucleic acids which are metabolized in a manner similar to naturally occurring nucleotides or at rates that are improved for the purposes desired.
  • the term also encompasses nucleic-acid-like structures with synthetic backbones.
  • One of skill in the art would recognize how to use a nucleic acid probes for screening of cancer cells in a sample by reference, for example, to U.S. Patent 6,326,148 , directed to screening of colon carcinoma cells.
  • Polypeptides associated with breast cancer can be quantified by image analysis using a suitable primary antibody against biomarkers, including but not limited to EGFR, HER-2, HER-3, IGFR, NDF, TGF- ⁇ , p-ERK, pS6, or p-AKT, detected directly or using an appropriate secondary antibody (such as rabbit anti-mouse IgG when using mouse primary antibodies) and/or a tertiary avidin (or Strepavidin) biotin complex (“ABC").
  • a suitable primary antibody against biomarkers including but not limited to EGFR, HER-2, HER-3, IGFR, NDF, TGF- ⁇ , p-ERK, pS6, or p-AKT, detected directly or using an appropriate secondary antibody (such as rabbit anti-mouse IgG when using mouse primary antibodies) and/or a tertiary avidin (or Strepavidin) biotin complex (“ABC").
  • reagents useful in the practice of the methods of the invention as exemplified herein include antibodies specific for HER2/neu, including but not limited to the mouse monoclonal antibody CB11, obtained from Ventana Medical Systems, Inc. (VMSI, Arlington, AZ).
  • reagents useful in the practice of the methods of the invention include antibodies specific for phosphorylated AKT, including but not limited to antibodies specific for a phosphorylated serine residue of position 473, wherein the sequence of AKT is represented by SEQ ID NO:1 (Table 8).
  • reagents useful in the practice of the methods of the invention include antibodies specific for phosphorylated S6, including but not limited to antibodies specific for a phosphorylated serine residue of position 235, wherein the sequence of S6 is represented by SEQ ID N0:2 (Table 8). Also, reagents useful in the practice of the methods of the invention include antibodies specific for phosphorylated ERK, including but not limited to antibodies specific for a phosphorylated threonine residue at position 202 and a phosphorylated tyrosine residue of position 204, wherein the sequence of ERK is represented by SEQ ID N0:3 (Table 8).
  • the pattern of expression, phosphorylation, or both expression and phosphorylation of the predictive polypeptides can be compared to a non-tumor tissue or cell sample.
  • the non-tumor tissue or cell sample can be obtained from a non-tumor tissue or cell sample from the same individual, or alternatively, a non-tumor tissue or cell sample from a different individual.
  • a detected pattern for a polypeptide is referred to as decreased in the mammalian tumor, tissue, or cell sample, if there is less polypeptide detected as compared to the a non-tumor tissue or cell sample.
  • a detected pattern for a polypeptide is referred to as increased in the mammalian tumor, tissue, or cell sample, if there is more polypeptide detected as compared to the a non-tumor tissue or cell sample.
  • a detected pattern for a polypeptide is referred to as normal in the mammalian tumor, tissue, or cell sample, if there is the same, or approximately the same, polypeptide detected as compared to the a non-tumor tissue or cell sample.
  • the methods of this invention for identifying mammalian tumors that respond, or that do not respond, to a HER2-directed therapy comprise the step of assaying a sample obtained from the mammalian tumor to detect a pattern of expression and/or phosphorylation of IGFR polypeptide in combination with the detection of a pattern of expression and/or increased or decreased phosphorylation of one or more polypeptides selected from (a) NDF polypeptide; (b) phosphorylated S6 ribosomal polypeptide; (c) phosphorylated AKT polypeptide.
  • the combination of polypeptides and pattern of expression, phosphorylation, or both expression and phosphorylation identifies mammalian tumors that respond, or that do not respond, to a HER2-directed therapy.
  • the methods can include the detection of a pattern of expression, phosphorylation or both of two, three or all four of these polypeptides. Further, the methods can, but need not, include other steps, including steps such as the detection of a pattern of expression, phosphorylation or both of different polypeptides.
  • the methods of this invention for selecting a subject with cancer for treatment, or to not receive treatment, with a molecule targeting HER2, such as, but not limited to treatment with rhuMAb HER2 (HERCEPTIN®), comprise the step of determining the pattern of expression, phosphorylation or both in a cell or tissue sample from the subject of one or a plurality of polypeptides consisting of: (a) IGFR polypeptide; (b) NDF polypeptide; (c) phosphorylated S6 ribosomal polypeptide; (d) phosphorylated AKT polypeptide.
  • the combination of polypeptides and pattern of expression, phosphorylation, or both expression and phosphorylation is used to select a subject with cancer for treatment, or to not receive treatment, with a molecule targeting HER2.
  • the methods can include the detection of a pattern of expression, phosphorylation or both of one, two, three, four, five, or all six of these polypeptides. Further, the methods can, but need not, include other steps, including steps such as the detection of a pattern of expression, phosphorylation or both of different polypeptides.
  • the pattern that identifies a mammalian tumor as responding or that can be used to select a subject with cancer for treatment with a molecule targeted to HER2 is normal or increased expression of IGFR polypeptide, accompanied by decreased phosphorylation of AKT polypeptide, decreased phosphorylation of S6 ribosomal polypeptide or both as compared to a non- tumor tissue or cell sample.
  • Further detected patterns include decreased expression of IGFR polypeptide, accompanied by increased phosphorylation of S6 ribosomal polypeptide as compared to a non-tumor tissue or cell sample.
  • the detected pattern is decreased expression of IGFR polypeptide, accompanied by increased expression of NDF polypeptide in the mammalian tumor as compared to a non-tumor tissue or cell sample; where further the detected pattern can include increased phosphorylation of S6 ribosomal polypeptide.
  • the pattern that identifies a mammalian tumor as not responding or that can be used to select a subject with cancer to not receive treatment with a molecule targeted to HER2 is normal or increased expression of IGFR polypeptide, accompanied by increased phosphorylation of AKT polypeptide, increased phosphorylation of S6 ribosomal polypeptide, or both as compared to a non-tumor tissue or cell sample.
  • the detected pattern is normal or increased expression of IGFR polypeptide and decreased expression of NDF as compared to a non-tumor tissue or cell sample.
  • staining procedures can be carried out by a person, such as a technician in the laboratory. Alternatively, the staining procedures can be carried out using automated systems. In either case, staining procedures for use according to the methods of this invention are preformed according to standard techniques and protocols well-established in the art.
  • tissue sample biological samples comprising cells, most preferably tumor cells, that are isolated from body samples, such as, but not limited to, smears, sputum, biopsies, secretions, cerebrospinal fluid, bile, blood, lymph fluid, urine and faeces, or tissue which has been removed from organs, such as breast, lung, intestine, skin, cervix, prostate, and stomach.
  • a tissue samples can comprise a region of functionally related cells or adjacent cells.
  • the amount of target protein is advantageously quantified by measuring the average optical density of the stained antigens.
  • the proportion or percentage of total tissue area stained can be readily calculated, for example as the area stained above a control level (such as an antibody threshold level) in the second image.
  • a control level such as an antibody threshold level
  • the percentage or amount of such cells in tissue derived from patients after treatment are compared to the percentage or amount of such cells in untreated tissue.
  • "determining" a pattern of expression, phosphorylation, or both expression and phosphorylation o polypeptides is understood broadly to mean merely obtaining the information on such polypeptide(s), either through direct examination or indirectly from, for example, a contract diagnostic service.
  • tissue sections taken from patients treated with rhuMAb HER2 (HERCEPTIN®) and chemotherapy are analyzed, according to the methods of this invention by immunohistochemistry for expression, phosphorylation, or expression and phosphorylation of erb-B ligands, receptors, downstream signaling proteins or any positive treatment response predictive combination thereof.
  • tissue microarrays are advantageously used in the methods of the invention, being well-validated method to rapidly screen multiple tissue samples under uniform staining and scoring conditions. ( Hoos et al., 2001, Am J Pathol. 158: 1245-51 ). Scoring of the stained arrays can be accomplished by an automated system that accurately quantified the staining observed.
  • results of this analysis identify biomarkers that best predict patient outcome following treatment, such as rhuMAb HER2 (HERCEPTIN®) therapies.
  • Patient "probability of response" ranging from 0 to 100 percent can be predicted based upon the expression, phosphorylation or both of a small set of ligands, receptors, signaling proteins or predictive combination thereof.
  • Additional samples from breast cancer patients can be analyzed, either as an alternative to or in addition to tissue microarray results. For example, analysis of samples from breast cancer patients can confirm the conclusions from the tissue arrays, if the patient's responses correlate with a specific pattern of receptor expression and/or downstream signaling.
  • kits for carrying out the methods of the invention are provided.
  • kits for characterizing a mammalian tumor's responsiveness to a HER2-directed therapy comprising an antibody that binds IGFR polypeptide, and one or more of the following: an antibody that binds phosphorylated AKT polypeptide; an antibody that binds phosphorylated S6 ribosomal polypeptide; and an antibody that binds NDF polypeptide.
  • the kit can include one, two, or all three of the following: an antibody that binds phosphorylated AKT polypeptide; an antibody that binds phosphorylated S6 ribosomal polypeptide; and an antibody that binds NDF polypeptide.
  • kit can include additional components other then the above-identified antibodies, including but not limited to additional antibodies.
  • additional antibodies such kits may be used, for example, by a clinician or physician as an aid to selecting an appropriate therapy for a particular patient, for example, a breast cancer patient under consideration for HER2-directed therapy.
  • Human tumor tissue sections were stained for predictive biomarkers according to the methods of the invention as follows. 10% Neutral Buffered Formalin Paraffin blocks were sectioned at 4 microns and the sections placed onto coated slides.
  • EGFR and HER2 immunostaining was performed by using the pre-diluted EGFR and HER2 antibodies from Ventana Medical Instruments, Inc. (VMSI, Arlington, AZ.).
  • HER3, Heregulin (NDF), and IGFR antibodies were obtained from NeoMarkers (Fremont, CA.).
  • TGF- ⁇ antibodies were obtained from Oncogene Sciences (San Diego, CA).
  • EGFR, HER2/neu, HER3, IGFR, Heregulin, and TGF- ⁇ were immunostained using the "BenchMark” (VMSI) with I-VIEW (VMSI) detection chemistry.
  • VMSI "BenchMark”
  • Antibodies specific for p-ERK (1:100), p-AKT (1:75), and phospho-S6 ribosomal protein were obtained from Cell Signaling Technology (Beverly, MA), and immunostained using a labeled streptavidin peroxidase technique. (Vector Elite ABC Kit, Burlingame, CA).
  • slides for p-S6 ribosomal protein, p-ERK and p-AKT were antigen retrieved using 0.1 M citrate buffer, pH 6.0 in the "decloaker” (Biocare Corp.) and the sections incubated overnight with the primary antibodies at 4°C. The next day, the slides were placed onto the Autostainer (Dako Corp.) and the "LSAB2" kit (Dako) was employed as the detection chemistry. DAB (Dako) was used as the chromogen. After immunostaining, all slides were counterstained manually with 4% ethyl green (Sigma).
  • Protein concentration was determined with a BioRad Protein Assay Kit (BioRad Laboratories, Hercules, CA). Equal amounts ofprotein, typically 15g protein per lane, were separated by gel electrophoresis, for example using pre-cast 4-12% Bis-Tris NuPage gradient gels (Invitrogen) or 7.5% or 4-15% gradient SDS-PAGE under reducing conditions, and transferred to membranes, such as HyBond-C nitrocellulose (Amersham Life Science) or Immobilon-P membranes. Membranes were blocked and then incubated with primary antibodies, for example antibodies against p-AKT and p-ERK (Cell Signaling Technology).
  • Antibody incubation was performed overnight at 4°C in Tris-buffered saline containing 3% bovine serum albumin/0.1% Tween 20. Signal was detected by chemiluminescence (PerkinElmer Life Sciences), or using a SuperSignal West Femto Maximum sensitivity substrate kit from Pierce (Rockford, IL) as described ( Xia et al., 2002, Oncogene 21: 6255-6263 ).
  • Immunohistochemistry for detecting and measuring predictive biomarker expression, activation or both was performed as follows. HER2/neu, EGFR, HER3, IGFR, TGF- ⁇ , Heregulin (NDF), p-ERK, p-AKT, and p-S6 ribosomal protein or phosphorylation levels were quantified using alkaline phosphatase or peroxidase techniques and microscope-based image analysis of immunohistochemically stained slides (as described in Bacus et al., 1997, Analyt. Quant. Cytol. Histol. 19: 316-328 ).
  • Quantification was by means of a CAS 200 image analyzer, as previously described ( Bacus & Ruby, 1993, Pathol Annu, 28: 179-204 ).
  • tumors were classified as negative or positive for each antibody based upon the level of staining.
  • Statistical analysis was performed using Systat to quantify frequencies and calculate Pearson Chi-squared tests of significance for interactions between variables.
  • the p value refers to the significance of the deviation of the distribution of samples from what would be expected based upon the overall population distribution. Comparisons were performed only on samples for which all relevant data were available. As a result, the number of patients included in most comparisons was slightly less then the total number of available samples.
  • VMSI Quantitative immunohistochemistry
  • VMSI Ventana Medical Scientific Instruments
  • Ser 437 anti- p-AKT
  • p-Erk1/2 were from Cell Signaling Technology Inc. (Beverly, MA)
  • antibodies to TGF ⁇ , erbB3, heregulin, and IGFR-1 were from NeoMarkers.
  • Tissue microarrays derived from 250 breast cancer patients who received conventional chemotherapy together with HERCEPTIN® were obtained from Clinomics Biosciences (Pittsfield, MA). The histology of the turners varied, with infiltrating ductal carcinoma being the most common. All patients had received post-surgical radiotherapy. The tissue samples in the array were taken before treatment. HER2/neu expression had been determined by using the HercepTest system (DAKO, Caprintera, CA) on the original biopsies for all patients. Patient response was based upon the case histories at last follow-up as decided by an independent pathologist provided by Clinomics.
  • DAKO HercepTest system
  • HercepTest staining scores were confirmed by analyzing HER2/neu expression levels using microarrays (data not shown). HER2/neu expression strongly correlated with patient response; 100% of the 0 or +1 HER2/neu patients relapsed while only 77% of the +3 patients relapsed. This response rate if similar to what has been reported previously (see Baselga, 2002, Annuals of Oncology 13: 8-9 ). Based on these results, further analysis of biomarkers concentrated on patients that expressed HER2 at the highest (+3) level. Of the samples that had the highest HercepTest scores (+3), seventy-four were taken from the primary tumor, two from lymph nodes, and one from an adrenal metastasis.
  • the analysis of receptor kinases revealed that, similar to HER2/neu, EGFR expression also significantly correlated with patient response (Table 2).
  • HERCEPTIN®-treated patients that over-expressed HER-2/neu, 30% of EGFR-positive patients had stable disease or were disease free, while only 9% of EGFR-negative patients did not progress.
  • seventy-seven +3 HER2/neu patients seventy of them expressed HER3; however, HER3 expression did not significantly correlate with patient response (although the low number ofHER3-negative patients limits this comparison in the data set).
  • the growth-factor receptor HER3 is thought to play an important role in downstream erbB signaling because it has a PI3-Kinase docking site and forms active heterodimers with the other erbB receptors.
  • the expression of other growth factor receptors may also mediate patient response, either through direct stimulation or downstream pathways or through transactivation of the erbB receptors.
  • the activation of heterodimers of HER2 with HER3 ⁇ or EGFR results in activation of the MAPK and PBK/AKT pathways.
  • the MAPK pathway was measured by analyzing the level of activation or phosphorylation of ERK (pERK). Analysis and comparison of the levels of activated ERK alone, among patients that overexpressed HER2/neu and who either had stable disease or who relapsed, failed to demonstrate any dramatic effect of elevated pERK levels as a factor for patient response (see Table 4). Similarly, based on this analysis, AKT activation (p-AKT) alone does not appear to be a predictive marker for response among HER2-positive patients treated with HERCEPTIN® (see Table 4).
  • Samples from seven breast cancer patients were obtained from Yale Univeristy. The clinical history of these seven patients varied, with some given HERCEPTIN® in combination with chemotherapy as a first line therapy while others were given HERCEPTIN® as an adjuvant therapy. These seven samples were analyzed for receptor, ligand, and signaling protein expression or phosphorylation, and the results compared to the results with the tissue microarray analysis.
  • Patient #7 was given HERCEPTIN® plus vinorelbine following the discovery of a solitary metastasis seven months after initial radiotherapy. After eight weeks of combination therapy there was progression of disease. Of the seven patients, three showed response to HERCEPTIN® while the other four failed to respond (Table 7).
  • One of the responders did not express IGFR but did express EGFR and showed positive downstream signaling.
  • the other one of these responders expressed IGFR and EGFR but did not show active downstream signaling in S6 or ERK.
  • All of the non-responders expressed IGFR and had positive S6 phosphorylation.
  • Two of the non-responders also expressed EGFR.
  • Receptor tyrosine kinase ligand expression versus patient response following therapy Analysis on tissue array samples for which clinical and Herceptest data was available and who over-expressed HER2/neu. Table 4. patient group n % responders %relapse P value p-ERK positive 36 25% 75% 0.43 p-ERK negative 39 33% 67% p-AKT positive 24 25% 75% 0.53 p-AKT negative 53 32% 68% p-S6 positive 27 33% 67% 0.74 p-S6 negative 44 30% 70%
  • NDF neg/p-S6 pos/IGFR neg 2 50% 50% 0.003 NDF neg/p-S6 neg/IGFR neg 9 11% 89% NDF neg/p-S6 neg/IGFR pos 4 0% 100% NDF neg/p-S6 pos/IGFR pos 4 0% 100% NDF pos/p-S6 pos/IGFR neg 7 100% 0% NDF pos/p-S6 neg/IGFR pos 16 44% 56% NDF pos/p-S6 neg/IGFR neg 14 36% 64% NDF neg/p-ERK pos/EGFR neg 3 0% 100% 0.08 NDF neg/p-ERK neg/EGFR neg 4 0% 100% NDF neg/p-ERK neg/EGFR pos 10 20% 80% NDF neg/p-ERK
  • AKT NP 005154 GI:4885061
  • S6 NP 001001, GI:17158044
  • AMINO ACIDS SEQ ID NO:2 See, e . g ., Pata et al., (1992) Gene 121 (2), 387-392 .
  • ERK (XP 055766, GI:20562757) 379 AMINO ACIDS (SEQ ID NO,3) See, e . g ., Butch et al., J Biol Chem., 1996., 271(8) :4230-5 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
EP03808454.7A 2002-12-11 2003-12-11 Method for predicting the response to her2-directed therapy Expired - Lifetime EP1570273B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43294202P 2002-12-11 2002-12-11
US432942P 2002-12-11
PCT/US2003/039770 WO2004053497A2 (en) 2002-12-11 2003-12-11 Method for predicting the response to her2-directed therapy

Publications (2)

Publication Number Publication Date
EP1570273A2 EP1570273A2 (en) 2005-09-07
EP1570273B1 true EP1570273B1 (en) 2018-05-30

Family

ID=32508018

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03808454.7A Expired - Lifetime EP1570273B1 (en) 2002-12-11 2003-12-11 Method for predicting the response to her2-directed therapy

Country Status (7)

Country Link
EP (1) EP1570273B1 (ja)
JP (1) JP4609930B2 (ja)
AU (1) AU2003302821B2 (ja)
CA (1) CA2509543C (ja)
DE (1) DE03808454T1 (ja)
ES (1) ES2246191T1 (ja)
WO (1) WO2004053497A2 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045991A1 (en) * 2004-10-25 2006-05-04 Astrazeneca Ab Method to predict whether a tumor will react to a chemotherapeutic treatment
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US8105768B2 (en) * 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
AU2006247067B2 (en) 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
JP4795203B2 (ja) * 2006-11-13 2011-10-19 シスメックス株式会社 アンスラサイクリン系抗癌剤の感受性判定方法及びそのシステム
CN103432580A (zh) 2007-03-02 2013-12-11 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CZ302709B6 (cs) * 2008-01-25 2011-09-14 Univerzita Palackého v Olomouci, Lékarská fakulta Zpusob zjištení senzitivity pacientu s nádorovým onemocnením na lécbu inhibitory HER-2 receptoru
NZ587420A (en) * 2008-02-25 2012-07-27 Prometheus Lab Inc Drug selection for breast cancer therapy using antibody-based arrays
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2544680B1 (en) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012092531A1 (en) 2010-12-29 2012-07-05 Expression Pathology, Inc. Her3 protein srm/mrm assay
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003741A1 (en) * 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU Y ET AL: "INSULIN-LIKE GROWTH FACTOR-I RECEPTOR SIGNALING AND RESISTANCE TO TRASTUZUMAB (HERCEPTIN)", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 93, no. 24, 19 December 2001 (2001-12-19), pages 1852 - 1857, XP008009958, ISSN: 0027-8874, DOI: 10.1093/JNCI/93.24.1852 *

Also Published As

Publication number Publication date
EP1570273A2 (en) 2005-09-07
CA2509543A1 (en) 2004-06-24
ES2246191T1 (es) 2006-02-16
WO2004053497A2 (en) 2004-06-24
CA2509543C (en) 2017-06-06
DE03808454T1 (de) 2006-01-26
JP2006509503A (ja) 2006-03-23
AU2003302821B2 (en) 2009-05-07
JP4609930B2 (ja) 2011-01-12
WO2004053497A3 (en) 2005-01-27
AU2003302821A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
US9239331B2 (en) Method for predicting the response to HER2-directed therapy
EP1570273B1 (en) Method for predicting the response to her2-directed therapy
US7771958B2 (en) Method for predicting response to epidermal growth factor receptor-directed therapy
JP5656406B2 (ja) 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
US7794960B2 (en) Predictive biomarkers in cancer therapy
US20060094068A1 (en) Predictive markers in cancer therapy
US7829297B2 (en) Treatment of cancers expressing p95 ErbB2
US20070059785A1 (en) Biomarkers in cancer
Słodkowska et al. Digital pathology in personalized cancer therapy
EP1301794A2 (en) Method for quantification of akt protein expression
WO2004000101A2 (en) Method for predicting response to her1/her2-directed therapy
Iwaya et al. CD10 Expression in Normal Breast and Breast Cancer Tissues

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050701

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

EL Fr: translation of claims filed
DET De: translation of patent claims
DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090223

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELL SIGNALING TECHNOLOGY, INC.

Owner name: VENTANA MEDICAL SYSTEMS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VENTANA MEDICAL SYSTEMS, INC.

Owner name: CELL SIGNALING TECHNOLOGY, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20180105

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1004152

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60351227

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180830

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180831

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1004152

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60351227

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181211

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20031211

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20221109

Year of fee payment: 20

Ref country code: FR

Payment date: 20221110

Year of fee payment: 20

Ref country code: DE

Payment date: 20221109

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20230101

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60351227

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20231210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20231210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20231210